董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Robert A. Michael Director,Chairman of the Board and Chief Executive Officer 55 3253.10万美元 57.43 2026-05-08
Melody B. Meyer Director 68 40.79万美元 1.65 2026-05-08
Frederick H. Waddell Director 72 40.29万美元 2.90 2026-05-08
Jennifer L. Davis Director 54 37.29万美元 0.25 2026-05-08
Susan E. Quaggin Director 62 35.95万美元 0.25 2026-05-08
Thomas J. Falk Director 67 未披露 未持股 2026-05-08
Roxanne Austin Director 65 43.29万美元 3.85 2026-05-08
Thomas C. Freyman Director 71 39.79万美元 13.46 2026-05-08
Thomas J. Falk Director 68 32.87万美元 0.42 2026-05-08
Brett J. Hart Director 56 39.79万美元 1.95 2026-05-08
William H.L. Burnside Director 74 38.29万美元 2.70 2026-05-08
Edward J. Rapp Director 68 38.34万美元 4.48 2026-05-08
Rebecca B. Roberts Director 73 37.29万美元 1.37 2026-05-08

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Robert A. Michael Director,Chairman of the Board and Chief Executive Officer 55 3253.10万美元 57.43 2026-05-08
Azita Saleki Gerhardt Executive Vice President, Chief Operations Officer 62 1079.20万美元 51.14 2026-05-08
Nicholas J. Donoghoe Chief Business and Strategy Officer and Executive Vice President 45 未披露 未持股 2026-05-08
Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer 57 1543.53万美元 30.28 2026-05-08
Perry C. Siatis Executive Vice President and General Counsel and Secretary 51 未披露 未持股 2026-05-08
Scott T. Reents Chief Financial Officer and Executive Vice President 58 1235.30万美元 18.95 2026-05-08
Roopal Thakkar Chief Scientific Officer and Executive Vice President, Research and Development 54 991.28万美元 11.38 2026-05-08
David R. Purdue Controller and Senior Vice President 48 未披露 未持股 2026-05-08
Demetris D. Crum Chief Human Resources Officer and Executive Vice President 45 未披露 未持股 2026-05-08

董事简历

中英对照 |  中文 |  英文
Robert A. Michael

Robert A. Michael自2017年3月1日起担任副总裁、总监。他于2015年成为Abbvie高管,并于2015年至2016年担任Abbvie副总裁、财务主管,2013年至2015年担任商业运营副总裁、财务规划和分析副总裁。在雅培,Michael先生从2010年到2012年担任营养供应链部门总监。Michael先生于1993年加入雅培。


Robert A. Michael previoly served as Chief Executive Officer starting in 2024 and President and Chief Operating Officer from July 2023 to June 2024, as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018. He served as AbbVie's Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Division Controller, Nutrition Supply Chain from 2010 to 2012. Mr. Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017.
Robert A. Michael自2017年3月1日起担任副总裁、总监。他于2015年成为Abbvie高管,并于2015年至2016年担任Abbvie副总裁、财务主管,2013年至2015年担任商业运营副总裁、财务规划和分析副总裁。在雅培,Michael先生从2010年到2012年担任营养供应链部门总监。Michael先生于1993年加入雅培。
Robert A. Michael previoly served as Chief Executive Officer starting in 2024 and President and Chief Operating Officer from July 2023 to June 2024, as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018. He served as AbbVie's Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Division Controller, Nutrition Supply Chain from 2010 to 2012. Mr. Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017.
Melody B. Meyer

Melody B. Meyer是一家私人咨询公司Melody Meyer Energy,LLC的总裁,自2016年6月起担任该职位。2011年3月至2016年4月,Meyer女士担任雪佛龙亚太勘探与生产公司总裁。她曾于2008年至2011年担任雪佛龙能源技术公司总裁,并在雪佛龙工作了37年,担任过各种其他职务。Meyer女士还是英国石油公司(BP P.I.C。)和国家油井公司(National Oilwell Varco,Inc.)的董事。


Melody B. Meyer,served as president of Chevron Asia Pacific Exploration and Production Company from March 2011 to April 2016. She previously served as president of Chevron Energy Technology Company from 2008 to 2011. Ms. Meyer held various leadership roles in global and U.S. locations during her thirty-seven year career at Chevron and retired in 2016. Ms. Meyer is president of Melody Meyer Energy, LLC, a private consulting firm, a position she has held since June 2016. Ms. Meyer is also a director at bp p.I.c. and NOV, Inc.
Melody B. Meyer是一家私人咨询公司Melody Meyer Energy,LLC的总裁,自2016年6月起担任该职位。2011年3月至2016年4月,Meyer女士担任雪佛龙亚太勘探与生产公司总裁。她曾于2008年至2011年担任雪佛龙能源技术公司总裁,并在雪佛龙工作了37年,担任过各种其他职务。Meyer女士还是英国石油公司(BP P.I.C。)和国家油井公司(National Oilwell Varco,Inc.)的董事。
Melody B. Meyer,served as president of Chevron Asia Pacific Exploration and Production Company from March 2011 to April 2016. She previously served as president of Chevron Energy Technology Company from 2008 to 2011. Ms. Meyer held various leadership roles in global and U.S. locations during her thirty-seven year career at Chevron and retired in 2016. Ms. Meyer is president of Melody Meyer Energy, LLC, a private consulting firm, a position she has held since June 2016. Ms. Meyer is also a director at bp p.I.c. and NOV, Inc.
Frederick H. Waddell

Frederick H. Waddell于1975年加入北方信托公司(Northern Trust Corporation),从2009年11月起担任董事会主席,直到2019年1月退休。此前,他曾于2008年至2017年担任首席执行官,2006年至2011年担任总裁,并于10月至2007年再次担任首席执行官。 2006年至2008年到2016年12月担任的首席运营官。此外,Waddell先生还是西北大学董事会成员和AbbVie Inc.董事。


Frederick H. Waddell,joined Northern Trust Corporation in 1975 and served as the chairman of the board from November 2009 until his retirement in January 2019. He previously served as chief executive officer from 2008 through 2017, as president from 2006 through 2011 and again from October to December 2016, and as chief operating officer from 2006 to 2008. Additionally, Mr. Waddell is a member of the Board of Trustees of the Art Institute of Chicago, the Chicago Symphony Orchestra, and Northwestern University, and a director of AbbVie Inc.
Frederick H. Waddell于1975年加入北方信托公司(Northern Trust Corporation),从2009年11月起担任董事会主席,直到2019年1月退休。此前,他曾于2008年至2017年担任首席执行官,2006年至2011年担任总裁,并于10月至2007年再次担任首席执行官。 2006年至2008年到2016年12月担任的首席运营官。此外,Waddell先生还是西北大学董事会成员和AbbVie Inc.董事。
Frederick H. Waddell,joined Northern Trust Corporation in 1975 and served as the chairman of the board from November 2009 until his retirement in January 2019. He previously served as chief executive officer from 2008 through 2017, as president from 2006 through 2011 and again from October to December 2016, and as chief operating officer from 2006 to 2008. Additionally, Mr. Waddell is a member of the Board of Trustees of the Art Institute of Chicago, the Chicago Symphony Orchestra, and Northwestern University, and a director of AbbVie Inc.
Jennifer L. Davis

Jennifer L. Davis,目前担任Procter & Gamble的首席执行官,负责医疗保健。


Jennifer L. Davis,currently serves as Chief Executive Officer, Health Care at Procter & Gamble.
Jennifer L. Davis,目前担任Procter & Gamble的首席执行官,负责医疗保健。
Jennifer L. Davis,currently serves as Chief Executive Officer, Health Care at Procter & Gamble.
Susan E. Quaggin

Susan E. Quaggin博士目前担任Northwestern University Feinberg School of Medicine的Irving S. Cutter教授和医学主席。


Susan E. Quaggin currently serves as the Irving S. Cutter Professor and Chair of Medicine at Northwestern University Feinberg School of Medicine.
Susan E. Quaggin博士目前担任Northwestern University Feinberg School of Medicine的Irving S. Cutter教授和医学主席。
Susan E. Quaggin currently serves as the Irving S. Cutter Professor and Chair of Medicine at Northwestern University Feinberg School of Medicine.
Thomas J. Falk
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Roxanne Austin

Roxanne Austin,担任加州私人投资和咨询公司--纽波特海岸奥斯汀投资顾问的总裁。自2004年以来,她担任一家私人投资咨询公司--奥斯汀投资顾问的总裁。从2009年7月至2010年7月,她还担任供应商互联网电视服务--移动网络公司的总裁兼首席执行官。2001年6月至2003年12月,她担任DIRECTV公司的总裁兼首席营运官。她还曾任休斯电子公司的执行副总裁兼首席财务官和德勤会计师事务所的合伙人。她也曾担任AbbVie公司、Target公司、Teledyne公司技术公司和爱立信公司的董事。


Roxanne Austin,has served as a member of board of directors since May 2021. Since December 2004 she has served as the President and Chief Executive Officer of Austin Investment Advisors, a private investment and consulting firm. From 2016 until 2023, she chaired the U.S. Mid-Market Investment Advisors Committee of EQT Partners, an investment organization. Previously, Ms. Austin has held a series of executive positions, including President and CEO of Move Networks, Inc. from 2008 to 2010, President and CEO of DIRECTV, Inc. from 2000 to 2004 and Executive Vice President and Chief Financial Officer of Hughes Electronics Corporation from 1997 to 2000. She is also a former partner of Deloitte & Touche LLP. Ms. Austin served on the board of directors of Target Corporation from 2002 to 2020 and on the board of directors of Abbott Laboratories Inc. from 2000 to April 2022. Ms. Austin currently serves on the boards of directors of several public companies including Verizon Communications, Inc., CrowdStrike Holdings, Inc., and AbbVie, Inc. Ms. Austin holds a B.B.A. in Accounting and Business Administration from the University of Texas at San Antonio.
Roxanne Austin,担任加州私人投资和咨询公司--纽波特海岸奥斯汀投资顾问的总裁。自2004年以来,她担任一家私人投资咨询公司--奥斯汀投资顾问的总裁。从2009年7月至2010年7月,她还担任供应商互联网电视服务--移动网络公司的总裁兼首席执行官。2001年6月至2003年12月,她担任DIRECTV公司的总裁兼首席营运官。她还曾任休斯电子公司的执行副总裁兼首席财务官和德勤会计师事务所的合伙人。她也曾担任AbbVie公司、Target公司、Teledyne公司技术公司和爱立信公司的董事。
Roxanne Austin,has served as a member of board of directors since May 2021. Since December 2004 she has served as the President and Chief Executive Officer of Austin Investment Advisors, a private investment and consulting firm. From 2016 until 2023, she chaired the U.S. Mid-Market Investment Advisors Committee of EQT Partners, an investment organization. Previously, Ms. Austin has held a series of executive positions, including President and CEO of Move Networks, Inc. from 2008 to 2010, President and CEO of DIRECTV, Inc. from 2000 to 2004 and Executive Vice President and Chief Financial Officer of Hughes Electronics Corporation from 1997 to 2000. She is also a former partner of Deloitte & Touche LLP. Ms. Austin served on the board of directors of Target Corporation from 2002 to 2020 and on the board of directors of Abbott Laboratories Inc. from 2000 to April 2022. Ms. Austin currently serves on the boards of directors of several public companies including Verizon Communications, Inc., CrowdStrike Holdings, Inc., and AbbVie, Inc. Ms. Austin holds a B.B.A. in Accounting and Business Administration from the University of Texas at San Antonio.
Thomas C. Freyman

Thomas C. Freyman,他曾担任Allergan的董事(从2018年到2020年AbbVie收购Allergan plc)。他曾担任Abbott Laboratories的执行副总裁,负责财务和管理(从2015年到2017年退休)。自2004年以来,目前一直担任雅培公司首席财务官、财务执行副总裁。2001年,首次被任命为首席财务官以及财务高级副总裁。1999年至2001年,担任雅培医疗部门的副总裁兼主管。在那之前,他担任了很多财务计划分析职位,包括:雅培国际运作的财务秘书以及公司副总裁兼财务秘书。他获得伊利诺伊大学的本科会计学士学位以及西北大学的工商管理硕士学位。


Thomas C. Freyman,served as a director at Allergan from 2018 to 2020, when AbbVie acquired Allergan plc. Mr. Freyman previously served as executive vice president, finance and administration at Abbott Laboratories from 2015 until his retirement in 2017. He previously served at Abbott as chief financial officer and executive vice president, finance and was first appointed chief financial officer and senior vice president, finance in 2001. Mr. Freyman previously served as a director of Tenneco Inc. from 2013 to 2022 and Hanger, Inc. from 2017 to 2022.
Thomas C. Freyman,他曾担任Allergan的董事(从2018年到2020年AbbVie收购Allergan plc)。他曾担任Abbott Laboratories的执行副总裁,负责财务和管理(从2015年到2017年退休)。自2004年以来,目前一直担任雅培公司首席财务官、财务执行副总裁。2001年,首次被任命为首席财务官以及财务高级副总裁。1999年至2001年,担任雅培医疗部门的副总裁兼主管。在那之前,他担任了很多财务计划分析职位,包括:雅培国际运作的财务秘书以及公司副总裁兼财务秘书。他获得伊利诺伊大学的本科会计学士学位以及西北大学的工商管理硕士学位。
Thomas C. Freyman,served as a director at Allergan from 2018 to 2020, when AbbVie acquired Allergan plc. Mr. Freyman previously served as executive vice president, finance and administration at Abbott Laboratories from 2015 until his retirement in 2017. He previously served at Abbott as chief financial officer and executive vice president, finance and was first appointed chief financial officer and senior vice president, finance in 2001. Mr. Freyman previously served as a director of Tenneco Inc. from 2013 to 2022 and Hanger, Inc. from 2017 to 2022.
Thomas J. Falk

Thomas J. Falk自2003年开始担任金伯利公司董事会主席以及首席执行官;自2002年开始担任首席执行官;自1999年到2002年担任公司总裁以及首席运营官;自1983年加入金伯利公司以来担任各类高级管理职务;自2003年到2009年担任Centex公司董事,该公司2009年被普尔特房屋公司收购;目前担任分营利性机构董事,包括催化剂股份有限公司、威斯康辛大学基金会以及消费者物品论坛,同时在美国男孩&女孩俱乐部担任主管。


Thomas J. Falk,Executive Chairman of Kimberly-Clark Corporation from January 2019 through December 2019;Chairman and CEO of Kimberly-Clark from 2003 until December 2018 (CEO since 2002);President and COO of Kimberly-Clark from 1999 to 2002.
Thomas J. Falk自2003年开始担任金伯利公司董事会主席以及首席执行官;自2002年开始担任首席执行官;自1999年到2002年担任公司总裁以及首席运营官;自1983年加入金伯利公司以来担任各类高级管理职务;自2003年到2009年担任Centex公司董事,该公司2009年被普尔特房屋公司收购;目前担任分营利性机构董事,包括催化剂股份有限公司、威斯康辛大学基金会以及消费者物品论坛,同时在美国男孩&女孩俱乐部担任主管。
Thomas J. Falk,Executive Chairman of Kimberly-Clark Corporation from January 2019 through December 2019;Chairman and CEO of Kimberly-Clark from 2003 until December 2018 (CEO since 2002);President and COO of Kimberly-Clark from 1999 to 2002.
Brett J. Hart

Brett J. Hart,2012年2月以来,他一直担任执行副总裁、总法律顾问和秘书。从2010年12月到2012年2月,他担任UAL、United和Continental的高级副总裁、总法律顾问和秘书。从2009年6月到2010年12月,他担任Sara Lee Corporation的执行副总裁、总法律顾问和公司秘书。从2005年3月到2009年5月,他担任 Sara Lee Corporatio的副总法律顾问和全球首席合规官。他于2010年加入UAL。


Brett J. Hart has served as President of UAL and United since May 2020. From March 2019 to May 2020, he served as Executive Vice President and Chief Administrative Officer of UAL and United. From May 2017 to March 2019, he served as Executive Vice President, Chief Administrative Officer and General Counsel of UAL and United. From February 2012 to May 2017, he served as Executive Vice President and General Counsel of UAL and United. Mr. Hart served as acting Chief Executive Officer and principal executive officer of the Company, on an interim basis, from October 2015 to March 2016. From December 2010 to February 2012, he served as Senior Vice President, General Counsel and Secretary of UAL, United and Continental. From June 2009 to December 2010, Mr. Hart served as Executive Vice President, General Counsel and Corporate Secretary at Sara Lee Corporation, a consumer food and beverage company. From March 2005 to May 2009, Mr. Hart served as Deputy General Counsel and Chief Global Compliance Officer of Sara Lee Corporation.
Brett J. Hart,2012年2月以来,他一直担任执行副总裁、总法律顾问和秘书。从2010年12月到2012年2月,他担任UAL、United和Continental的高级副总裁、总法律顾问和秘书。从2009年6月到2010年12月,他担任Sara Lee Corporation的执行副总裁、总法律顾问和公司秘书。从2005年3月到2009年5月,他担任 Sara Lee Corporatio的副总法律顾问和全球首席合规官。他于2010年加入UAL。
Brett J. Hart has served as President of UAL and United since May 2020. From March 2019 to May 2020, he served as Executive Vice President and Chief Administrative Officer of UAL and United. From May 2017 to March 2019, he served as Executive Vice President, Chief Administrative Officer and General Counsel of UAL and United. From February 2012 to May 2017, he served as Executive Vice President and General Counsel of UAL and United. Mr. Hart served as acting Chief Executive Officer and principal executive officer of the Company, on an interim basis, from October 2015 to March 2016. From December 2010 to February 2012, he served as Senior Vice President, General Counsel and Secretary of UAL, United and Continental. From June 2009 to December 2010, Mr. Hart served as Executive Vice President, General Counsel and Corporate Secretary at Sara Lee Corporation, a consumer food and beverage company. From March 2005 to May 2009, Mr. Hart served as Deputy General Counsel and Chief Global Compliance Officer of Sara Lee Corporation.
William H.L. Burnside

William H.L. Burnside,Burnside先生是The Boston Consulting Group BCG的一位退休高级副总裁兼董事,目前担任顾问。在1987年成为BCG洛杉矶办事处的管理合伙人之前,他曾在BCG的伦敦和芝加哥办事处任职,为电信,媒体,国防,金融服务和制造业的客户提供服务。Burnside先生是南加州和奥杜邦加利福尼亚州执行服务部门的董事。


William H.L. Burnside,is a retired senior vice president and director at The Boston Consulting Group (BCG), where he currently serves as an advisor. Prior to becoming managing partner of BCG's Los Angeles office in 1987, he worked in BCG's London and Chicago offices, servicing clients in telecommunications, media, defense, financial services, and manufacturing.
William H.L. Burnside,Burnside先生是The Boston Consulting Group BCG的一位退休高级副总裁兼董事,目前担任顾问。在1987年成为BCG洛杉矶办事处的管理合伙人之前,他曾在BCG的伦敦和芝加哥办事处任职,为电信,媒体,国防,金融服务和制造业的客户提供服务。Burnside先生是南加州和奥杜邦加利福尼亚州执行服务部门的董事。
William H.L. Burnside,is a retired senior vice president and director at The Boston Consulting Group (BCG), where he currently serves as an advisor. Prior to becoming managing partner of BCG's Los Angeles office in 1987, he worked in BCG's London and Chicago offices, servicing clients in telecommunications, media, defense, financial services, and manufacturing.
Edward J. Rapp

Edward J. Rapp 曾担任 Caterpillar Inc. 资源行业集团总裁。此前,他于2013年至2014年在新加坡担任 Caterpillar 集团总裁,于2010年至2013年担任首席财务官,并于2007年被任命为集团总裁。他还担任 Xos, Inc. 的董事。他目前是 University of Missouri 商学院顾问委员会的成员。Rapp 先生曾担任 FM Global 的董事。


Edward J. Rapp,served as the Caterpillar Inc. group president for resource industries. He previously served at Caterpillar as group president based in Singapore in 2013 and 2014 and as the chief financial officer from 2010 to 2013, and he was named a group president in 2007. He also serves as a director of Xos, Inc. He is currently a member of the University of Missouri College of Business Advisory Board. Mr. Rapp previously served as a director of FM Global.
Edward J. Rapp 曾担任 Caterpillar Inc. 资源行业集团总裁。此前,他于2013年至2014年在新加坡担任 Caterpillar 集团总裁,于2010年至2013年担任首席财务官,并于2007年被任命为集团总裁。他还担任 Xos, Inc. 的董事。他目前是 University of Missouri 商学院顾问委员会的成员。Rapp 先生曾担任 FM Global 的董事。
Edward J. Rapp,served as the Caterpillar Inc. group president for resource industries. He previously served at Caterpillar as group president based in Singapore in 2013 and 2014 and as the chief financial officer from 2010 to 2013, and he was named a group president in 2007. He also serves as a director of Xos, Inc. He is currently a member of the University of Missouri College of Business Advisory Board. Mr. Rapp previously served as a director of FM Global.
Rebecca B. Roberts

Rebecca B. Roberts,2006年起担任雪佛龙管线公司总裁,直至2011年退休。她在此之前曾于2003年至2006年担任雪佛龙全球发电公司总裁,此外在雪佛龙三十六年的职业生涯中还担任过多个技术和管理职位。罗伯茨女士的职业生涯始于化学家和研究科学家。Roberts女士目前在Black Hills Corporation和MSA Safety Incorporated的董事会任职。Roberts女士于2015年至2018年担任安桥,Inc.的董事。


Rebecca B. Roberts,served as president of Chevron Pipe Line Company from 2006 until her retirement in 2011. She previously served as the president of Chevron Global Power Generation from 2003 to 2006, in addition to various technical and management positions during her thirty-six year career with Chevron. Ms. Roberts began her career as a chemist and research scientist. Ms. Roberts currently serves on the board of directors at Black Hills Corporation and MSA Safety Incorporated. Ms. Roberts served as a director of Enbridge, Inc. from 2015 to 2018.
Rebecca B. Roberts,2006年起担任雪佛龙管线公司总裁,直至2011年退休。她在此之前曾于2003年至2006年担任雪佛龙全球发电公司总裁,此外在雪佛龙三十六年的职业生涯中还担任过多个技术和管理职位。罗伯茨女士的职业生涯始于化学家和研究科学家。Roberts女士目前在Black Hills Corporation和MSA Safety Incorporated的董事会任职。Roberts女士于2015年至2018年担任安桥,Inc.的董事。
Rebecca B. Roberts,served as president of Chevron Pipe Line Company from 2006 until her retirement in 2011. She previously served as the president of Chevron Global Power Generation from 2003 to 2006, in addition to various technical and management positions during her thirty-six year career with Chevron. Ms. Roberts began her career as a chemist and research scientist. Ms. Roberts currently serves on the board of directors at Black Hills Corporation and MSA Safety Incorporated. Ms. Roberts served as a director of Enbridge, Inc. from 2015 to 2018.

高管简历

中英对照 |  中文 |  英文
Robert A. Michael

Robert A. Michael自2017年3月1日起担任副总裁、总监。他于2015年成为Abbvie高管,并于2015年至2016年担任Abbvie副总裁、财务主管,2013年至2015年担任商业运营副总裁、财务规划和分析副总裁。在雅培,Michael先生从2010年到2012年担任营养供应链部门总监。Michael先生于1993年加入雅培。


Robert A. Michael previoly served as Chief Executive Officer starting in 2024 and President and Chief Operating Officer from July 2023 to June 2024, as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018. He served as AbbVie's Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Division Controller, Nutrition Supply Chain from 2010 to 2012. Mr. Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017.
Robert A. Michael自2017年3月1日起担任副总裁、总监。他于2015年成为Abbvie高管,并于2015年至2016年担任Abbvie副总裁、财务主管,2013年至2015年担任商业运营副总裁、财务规划和分析副总裁。在雅培,Michael先生从2010年到2012年担任营养供应链部门总监。Michael先生于1993年加入雅培。
Robert A. Michael previoly served as Chief Executive Officer starting in 2024 and President and Chief Operating Officer from July 2023 to June 2024, as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018. He served as AbbVie's Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Division Controller, Nutrition Supply Chain from 2010 to 2012. Mr. Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017.
Azita Saleki Gerhardt

Azita Saleki Gerhardt博士,她目前担任AbbVie Inc.的执行副总裁,负责运营,这是一家全球研究驱动的生物制药公司,致力于为一些世界上最复杂和关键的条件开发创新的先进疗法,此前曾担任运营高级副总裁(从2013年到2018年)。艾伯维(AbbVie)成立于2013年,是雅培(Abbott Laboratories)的子公司。她在Abbott Laboratories工作了20多年,担任各种高级管理职位,专注于运营、制造和质量。


Azita Saleki Gerhardt is an executive with extensive experience leading the operations function of a global biopharmaceutical company. She has served as the Executive Vice President, Chief Operations Officer at AbbVie Inc. ("AbbVie"), a global, research driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions, since July 2023. Dr. Saleki Gerhardt previoly served as AbbVie's Executive Vice President, Operations from 2018 until July 2023, and Senior Vice President, Operations from 2013 to 2018. AbbVie was formed in 2013 as a spin off from Abbott Laboratories. She spent more than tnty years at Abbott Laboratories in a variety of senior management roles foced on operations, manufacturing and quality.
Azita Saleki Gerhardt博士,她目前担任AbbVie Inc.的执行副总裁,负责运营,这是一家全球研究驱动的生物制药公司,致力于为一些世界上最复杂和关键的条件开发创新的先进疗法,此前曾担任运营高级副总裁(从2013年到2018年)。艾伯维(AbbVie)成立于2013年,是雅培(Abbott Laboratories)的子公司。她在Abbott Laboratories工作了20多年,担任各种高级管理职位,专注于运营、制造和质量。
Azita Saleki Gerhardt is an executive with extensive experience leading the operations function of a global biopharmaceutical company. She has served as the Executive Vice President, Chief Operations Officer at AbbVie Inc. ("AbbVie"), a global, research driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions, since July 2023. Dr. Saleki Gerhardt previoly served as AbbVie's Executive Vice President, Operations from 2018 until July 2023, and Senior Vice President, Operations from 2013 to 2018. AbbVie was formed in 2013 as a spin off from Abbott Laboratories. She spent more than tnty years at Abbott Laboratories in a variety of senior management roles foced on operations, manufacturing and quality.
Nicholas J. Donoghoe

Nicholas J. Donoghoe是AbbVie企业创新高级副总裁。 他之前曾在麦肯锡公司(McKinsey&Company)担任合伙人,领导该公司的西海岸制药和生物技术业务。 Donoghoe博士于2007年加入公司,并支持在肿瘤学,免疫学和基层医疗等治疗领域的多次成功推出。 他于2019年加入AbbVie。


Nicholas J. Donoghoe previoly served as AbbVie's Senior Vice President, Chief Operating Officer, R&D from 2022 to 2023, as Senior Vice President, Portfolio Innovation from 2021 to 2022, as Senior Vice President, Global Strategy and Operations, Allergan Aesthetics, from 2020 to 2021, and as Senior Vice President, Enterprise Innovation from 2019 to 2020. Dr. Donoghoe was first appointed as an AbbVie corporate officer in January 2019 when he joined AbbVie. Prior to joining AbbVie, he served as a Partner at McKinsey & Company where he was a leader of the firm's Pharma and Biotechnology practice for over a decade.
Nicholas J. Donoghoe是AbbVie企业创新高级副总裁。 他之前曾在麦肯锡公司(McKinsey&Company)担任合伙人,领导该公司的西海岸制药和生物技术业务。 Donoghoe博士于2007年加入公司,并支持在肿瘤学,免疫学和基层医疗等治疗领域的多次成功推出。 他于2019年加入AbbVie。
Nicholas J. Donoghoe previoly served as AbbVie's Senior Vice President, Chief Operating Officer, R&D from 2022 to 2023, as Senior Vice President, Portfolio Innovation from 2021 to 2022, as Senior Vice President, Global Strategy and Operations, Allergan Aesthetics, from 2020 to 2021, and as Senior Vice President, Enterprise Innovation from 2019 to 2020. Dr. Donoghoe was first appointed as an AbbVie corporate officer in January 2019 when he joined AbbVie. Prior to joining AbbVie, he served as a Partner at McKinsey & Company where he was a leader of the firm's Pharma and Biotechnology practice for over a decade.
Jeffrey R. Stewart

Jeffrey R. Stewart是艾伯维(AbbVie)美国商业运营高级副总裁。 斯图尔特先生曾于2013年至2018年担任AbbVie商业运营总裁。在AbbVie从雅培离职之前,他曾担任美国雅培专有制药部门副总裁。 斯图尔特先生于1992年加入雅培。


Jeffrey R. Stewart previoly served as Senior Vice President, U.S. Commercial Operations from 2018 to 2020 and as AbbVie's President, U.S. Commercial Operations from 2013 to 2018. Prior to AbbVie's separation from Abbott, he served as Vice President, Abbott Proprietary Pharmaceutical Division, United States. Mr. Stewart joined Abbott in 1992 and was first appointed as an AbbVie corporate officer in December 2018.
Jeffrey R. Stewart是艾伯维(AbbVie)美国商业运营高级副总裁。 斯图尔特先生曾于2013年至2018年担任AbbVie商业运营总裁。在AbbVie从雅培离职之前,他曾担任美国雅培专有制药部门副总裁。 斯图尔特先生于1992年加入雅培。
Jeffrey R. Stewart previoly served as Senior Vice President, U.S. Commercial Operations from 2018 to 2020 and as AbbVie's President, U.S. Commercial Operations from 2013 to 2018. Prior to AbbVie's separation from Abbott, he served as Vice President, Abbott Proprietary Pharmaceutical Division, United States. Mr. Stewart joined Abbott in 1992 and was first appointed as an AbbVie corporate officer in December 2018.
Perry C. Siatis

Perry C. Siatis是AbbVie的执行副总裁、总法律顾问和秘书。Siatis先生曾于2021年9月至2022年10月担任高级副总裁兼副总法律顾问。2013年至2021年,Siatis先生还担任过各种职务,包括高级副总裁、法律和首席道德与合规官;法律交易和研发/联盟管理高级副总裁兼首席道德与合规官;生物战略发展和法律监管副总裁。Siatis先生于2005年加入Abbott,并于2022年10月首次被任命为AbbVie公司高管。


Perry C. Siatis previoly served as Senior Vice President, Deputy General Counsel from September 2021 until October 2022. From 2013 until 2021, Mr. Siatis also served in vario roles including as Senior Vice President, Legal and Chief Ethics and Compliance Officer, as Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer, and as Vice President, Biologic Strategic Development and Legal Regulatory. Mr. Siatis joined Abbott in 2005 and was first appointed as an AbbVie corporate officer in October 2022.
Perry C. Siatis是AbbVie的执行副总裁、总法律顾问和秘书。Siatis先生曾于2021年9月至2022年10月担任高级副总裁兼副总法律顾问。2013年至2021年,Siatis先生还担任过各种职务,包括高级副总裁、法律和首席道德与合规官;法律交易和研发/联盟管理高级副总裁兼首席道德与合规官;生物战略发展和法律监管副总裁。Siatis先生于2005年加入Abbott,并于2022年10月首次被任命为AbbVie公司高管。
Perry C. Siatis previoly served as Senior Vice President, Deputy General Counsel from September 2021 until October 2022. From 2013 until 2021, Mr. Siatis also served in vario roles including as Senior Vice President, Legal and Chief Ethics and Compliance Officer, as Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer, and as Vice President, Biologic Strategic Development and Legal Regulatory. Mr. Siatis joined Abbott in 2005 and was first appointed as an AbbVie corporate officer in October 2022.
Scott T. Reents

Scott T. Reents是AbbVie的执行副总裁兼首席财务官。他曾于2022年6月至2022年11月担任高级副总裁兼首席财务官,2019年至2022年6月份担任税务和财政部副总裁,2013年至2019年担任税务部副总裁。Reents先生于2008年加入Abbott,并于2022年6月首次被任命为AbbVie公司高管。


Scott T. Reents previoly served as Senior Vice President, Chief Financial Officer from June 2022 to November 2022, as Vice President, Tax and Treasury from 2019 to June 2022, and as Vice President, Tax from 2013 to 2019. Mr. Reents joined Abbott in 2008 and was first appointed as an AbbVie corporate officer in June 2022.
Scott T. Reents是AbbVie的执行副总裁兼首席财务官。他曾于2022年6月至2022年11月担任高级副总裁兼首席财务官,2019年至2022年6月份担任税务和财政部副总裁,2013年至2019年担任税务部副总裁。Reents先生于2008年加入Abbott,并于2022年6月首次被任命为AbbVie公司高管。
Scott T. Reents previoly served as Senior Vice President, Chief Financial Officer from June 2022 to November 2022, as Vice President, Tax and Treasury from 2019 to June 2022, and as Vice President, Tax from 2013 to 2019. Mr. Reents joined Abbott in 2008 and was first appointed as an AbbVie corporate officer in June 2022.
Roopal Thakkar

Roopal Thakkar,担任艾伯维全球治疗高级副总裁、首席医疗官。此前,他曾于2022年底至2023年12月初担任艾伯维发展和监管事务高级副总裁兼首席医疗官,并于2019年至2022年担任全球监管事务和研发质量保证副总裁,并于2015年至2019年担任全球监管事务副总裁。Thakkar博士于2003年加入雅培,并于2023年12月首次被任命为公司高管。


Roopal Thakkar previoly served as Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie from 2022 until 2023, as Vice President, Global Regulatory Affairs and R&D Quality Assurance from 2019 to 2022, and as Vice President, Global Regulatory Affairs from 2015 to 2019. Dr. Thakkar joined Abbott in 2003 and was first appointed as an AbbVie corporate officer in December 2023.
Roopal Thakkar,担任艾伯维全球治疗高级副总裁、首席医疗官。此前,他曾于2022年底至2023年12月初担任艾伯维发展和监管事务高级副总裁兼首席医疗官,并于2019年至2022年担任全球监管事务和研发质量保证副总裁,并于2015年至2019年担任全球监管事务副总裁。Thakkar博士于2003年加入雅培,并于2023年12月首次被任命为公司高管。
Roopal Thakkar previoly served as Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie from 2022 until 2023, as Vice President, Global Regulatory Affairs and R&D Quality Assurance from 2019 to 2022, and as Vice President, Global Regulatory Affairs from 2015 to 2019. Dr. Thakkar joined Abbott in 2003 and was first appointed as an AbbVie corporate officer in December 2023.
David R. Purdue

David R. Purdue,自2022年起担任AbbVie的副总裁兼财务总监,负责商业运营。Purdue先生曾担任AbbVie的副总裁兼财务主管;财务规划与分析副总裁;在AbbVie和Abbott Laboratories (AbbVie的前母公司)担任财务整合领导副总裁和其他财务组织职务。Purdue先生于2003年加入Abbott Laboratories。


David R. Purdue previoly served as AbbVie's Vice President, Controller, Commercial Operations from 2023 to 2025, Vice President, Corporate Treasurer from 2022 to 2023, Vice President, Corporate Financial Planning and Analysis from 2020 to 2022, and Vice President, Allergan Integration from 2019 to 2020. Mr. Purdue joined Abbott in 2003 and was first appointed as an AbbVie corporate officer in March 2025.
David R. Purdue,自2022年起担任AbbVie的副总裁兼财务总监,负责商业运营。Purdue先生曾担任AbbVie的副总裁兼财务主管;财务规划与分析副总裁;在AbbVie和Abbott Laboratories (AbbVie的前母公司)担任财务整合领导副总裁和其他财务组织职务。Purdue先生于2003年加入Abbott Laboratories。
David R. Purdue previoly served as AbbVie's Vice President, Controller, Commercial Operations from 2023 to 2025, Vice President, Corporate Treasurer from 2022 to 2023, Vice President, Corporate Financial Planning and Analysis from 2020 to 2022, and Vice President, Allergan Integration from 2019 to 2020. Mr. Purdue joined Abbott in 2003 and was first appointed as an AbbVie corporate officer in March 2025.
Demetris D. Crum

Demetris D. Crum previoly于2022年8月至2025年6月期间担任副总裁,Total Rewards,于2022年1月至2022年8月期间担任副总裁,薪酬,并于2020年8月至2022年1月期间担任Biness Human Resces公司员工职能副总裁。Crum先生于2017年加入艾伯维,并于2025年7月首次被任命为艾伯维公司高管。在加入艾伯维公司之前,Crum先生曾在卡夫亨氏公司和百事可乐担任过多个人力资源领导职务。


Demetris D. Crum previoly served as Vice President, Total Rewards from Augt 2022 to June 2025, as Vice President, Compensation from January 2022 to Augt 2022, and as Vice President, Biness Human Resces for corporate staff functions from Augt 2020 to January 2022. Mr. Crum joined AbbVie in 2017 and was first appointed as an AbbVie corporate officer in July 2025. Prior to joining AbbVie, Mr. Crum held several human resces leadership roles at The Kraft Heinz Company and PepsiCo.
Demetris D. Crum previoly于2022年8月至2025年6月期间担任副总裁,Total Rewards,于2022年1月至2022年8月期间担任副总裁,薪酬,并于2020年8月至2022年1月期间担任Biness Human Resces公司员工职能副总裁。Crum先生于2017年加入艾伯维,并于2025年7月首次被任命为艾伯维公司高管。在加入艾伯维公司之前,Crum先生曾在卡夫亨氏公司和百事可乐担任过多个人力资源领导职务。
Demetris D. Crum previoly served as Vice President, Total Rewards from Augt 2022 to June 2025, as Vice President, Compensation from January 2022 to Augt 2022, and as Vice President, Biness Human Resces for corporate staff functions from Augt 2020 to January 2022. Mr. Crum joined AbbVie in 2017 and was first appointed as an AbbVie corporate officer in July 2025. Prior to joining AbbVie, Mr. Crum held several human resces leadership roles at The Kraft Heinz Company and PepsiCo.